Supplementary figure 1



Supplementary figure 1. Viability of *L. amazonensis* amastigotes after PFA or heat inactivation. Axenic amastigotes of *L. amazonensis* were treated as described in figure 1D. After washes, the samples were incubated in complete promastigote media at 26^{o} C and counted on the 3rd and 5th day of culture. Graph corresponds to the number of promastigotes per ml as a representative result of 3 independent assays.

Supplementary figure 2



Supplementary figure 2. *L. amazonensis* infection in BMMs from WT or *TLR*-/- mice. Percentage of infection for the experiment in Figure 2B. Data correspond to the mean ± SD of triplicates. Results represent 3 independent experiments. No statistical differences were observed by using the Student *t*-test.

Supplementary figure 3



Supplementary figure 3. Progression of *L. amazonensis* lesions in WT and *TLR9*$^{-/-}$ mice. (A) Lesion size (mm) expressed as the mean ± SD from at least n=5 mice per group. The arrow indicates the week of sacrifice of mice for parasite load determination (shown in Fig. 4C). Representative image of the lesion from WT or *TLR9*$^{-/-}$ mice infected by *L. amazonensis* on the left footpad compared to the non-infected footpad (right). **(B)** Detection of IL-1β, TNF-α and IL-12p40 in the footpad homogenates at the third week of *Leishmania* infection and quantified by ELISA. Results correspond to the mean ± SD (n=4). n.s: not significant; (Student's *t*-test). **(C)** Parasite load in the footpads of WT and *TLR9*$^{-/-}$ mice infected with *L. amazonensis* at the fifth week of infection. Results correspond to mean ± SD (n=4). **p= 0.0028 (Student's *t*-test).

Supplementary figure 4



F

CD200:
5'-AAC CCT TGA TTG TGA CAT GGC- 3' ; 5'-CCC AGC TCT GTG ACA TTT ATC CT-3'
iNOS:
5'-CAG CTG GGC TGT ACA AAC CTT -3' ; 5'-CAT TGG AAG TGA AGC GTT TCG -3'
HPRT-1:
5'-TCA GTC AAC GGG GGA CAT AAA-3' ; 5'-GGG GCT GTA CTG CTT AAC CAG-3'
IL-1β:
5'-TGG TGT GTG ACG TTC CCA TTA-3' ; 5'-CAG CAC GAG GCT TTT TTG TTG-3'
IL-4:
5'-GGC ATT TTG AAC GAG GTC ACA-3' ; 5'-AGG ACG TTT GGC ACA TCC A-3'
IL-10:
5'-GCT CTT ACT GAC TGG CAT GAG-3' ; 5'-CGC AGC TCT AGG AGC ATG TG-3'
IL-12:
5'-TGG TTT GCC ATC GTT TTG CTG-3' ; 5'-ACA GGT GAG GTT CAC TGT TTC T-3'

Supplementary figure 4. Gating strategy for macrophage immunophenotyping in the lesion of *L. amazonensis*-infected mice. Lesions were processed as described in the Methods and the resulting cells were evaluated by flow cytometry. (**A**) Debris exclusion based on forward versus side scatter parameters (FSC and SSC). (**B**) Single cell events (singlets) were selected based on FSC-H versus FSC-A parameters. (**C**) $CD45^+$ and $CD45^-$cells were gated for evaluation of $CD200^+$ in the entire population (**D**). (**E**) $CD45^-CD200^+$cells were obtained from the total number of cells (absolute population), analyzing the median fluorescence intensity (MFI). (**F**) List of oligonucleotide primers used for the qPCR.

Supplemental Table 1

Antibodies used in the study:

rabbit anti-mouse iNOS mAb	Abcam, ab136918
rabbit anti-mouse actin mAb	Imuny-VBP Biotecnologia Ltda, IM-0075
goat anti-mouse CD200	R&D Systems, AF2554
Anti-mouse CD200	BD Biosciences, clone OX-90
Anti-mouse CD45	Biolegend clone, 30-F11
Anti-mouse CD11b	BD Biosciences clone, M1/70
Anti-mouse CD11c	Biolegend, clone N418
Anti-mouse MHC class II	BD Biosciences, clone 2G9
Anti-mouse F4/80	eBiosciences, clone BM8
Anti-rabbit IgG conjugated Alexa Fluor 488	Thermo Fischer Scientific, A11070
Anti-IgG rabbit peroxidase-conjugated	Imuny-VBP Biotecnologia Ltda, IC-3R01
Anti-IgG mouse peroxidase-conjugated	Imuny-VBP Biotecnologia Ltda, IC-1G01